PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 11, 2022Journal of the American Society of Nephrology186 citationsOpen Access

Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial

View Full Paper
MPMichele ProvenzanoMPMaría Jesús PuchadesCGCarlo Garofalo

Key Points

Key points are not available for this paper at this time.

Abstract

European Union Clinical Trials Register, EU 2017-004641-25.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Provenzano et al. (2022) studied this question.

synapsesocial.com/papers/69d861fdc025a7c015bedc2ahttps://doi.org/10.1681/asn.2022020207
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy2019 · 6,164 citations
  2. 2Regulation of Potassium Homeostasis2014 · 529 citations
  3. 3Mechanisms in Hyperkalemic Renal Tubular Acidosis2009 · 166 citations
  4. 4An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function2011 · 364 citations
  5. 5Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial2019 · 204 citations